Rabi Hanna, MD
Primary Location
Cleveland Clinic Children's Outpatient Center
Treatment & Services
- Blood Tests
- Blood Transfusion
- Bone Marrow Transplant (BMT)
- Cancer Center
- Clinical Trials
- Department of Pediatric Hematology and Oncology
- Hepatic Chemoembolization
Specialty in Diseases & Conditions
- Adrenoleukodystrophy (ALD)
- Anaplastic Large Cell Lymphoma
- Aplastic Anemia
- B-Cell Prolymphocytic Leukemia
- Bone Marrow Failure Disorders
- Chronic Myeloid Leukemia (CML)
- Hepatosplenic T-Cell Lymphoma
- Immunodysregulation Polyendocrinopathy Enteropathy X-linked Syndrome (IPEX)
- Inherited Metabolic Disease
- Juvenile Myelomonocytic Leukemia
- Leukemia
- Lymphoma
- Myelodysplastic Syndrome (MDS)
- Neuroblastoma
- Paroxysmal Nocturnal Hemoglobinuria (PNH)
- Pediatric Rare Cancer and Blood Disease Program
- Peripheral T-Cell Lymphomas
- Post-Transplant Lymphoproliferative Disorder (PTLD)
- Primary Immunodeficiency Disease
- PTEN Hamartoma Tumor Syndrome
- Rare Cancer and Blood Disease Program
- Sickle Cell Anemia
- Solid Tumor Disorders
- T-Cell Lymphoma
- T-Cell Prolymphocytic Leukemia
- T-Lymphocyte Tolerance
Insurance
Is Cleveland Clinic Part of Your Insurance?
Review a list of accepted insurance plans for our Northeast Ohio locations or learn more about purchasing a contracted managed care plan.
View All PlansAbout Rabi Hanna, MD
Rabi Hanna, MD, is the director of the Pediatric Bone Marrow Transplantation at Cleveland Clinic Children’s Hospital, Department of Pediatric Hematology and Oncology. He sees patients on Main Campus.
Dr. Hanna is board certified in pediatrics and pediatric hematology-Oncology. He earned his medical degree from Aleppo University Faculty of Medicine in Aleppo, Syria. His post-graduate training in USA includes a pediatric residency at Duke University Medical Center in Durham, North Carolina, and a pediatric hematology-oncology fellowship at the Fred Hutchinson Cancer Research Center and Seattle Children’s Hospital in Seattle, Washington.
Dr. Hanna is a member of several professional organizations, including the American Society of Pediatric Hematology Oncology, American Society of Hematology, and the American Society of Bone Marrow Transplant.
Dr. Hanna has published several research articles in peer-reviewed journals, and has presented at professional association meetings.
His specialty interests include treatment of children with leukemia / Lymphoma and solid tumors that require Hematopoietic Stem Cell Transplantation to consolidate the treatment for their malignant disease, and he also very interested in treatment of inherited non-malignant disorders like primary immunodeficiency like SCID or other inherited metabolic diseases which Hematopoietic Stem Cell Transplantation could offer the potential to restore normal hematological and immunologic function.
He is especially interested in identifying successful conditioning treatments with less side effects especially for non-malignant diseases like hematological diseases (sickle cell disease, thalassemia major, severe aplastic anemia, Fanconi anemia, etc) or primary immune deficiency disorders, such as Severe Combined Immune deficiency, Wiskott-Aldrich Syndrome, and IPEX.
His clinical research is aimed at identifying genetic factors that affect outcomes post bone marrow transplantation from unrelated donor. He is also exploring the role of hematopoietic and mesenchymal stem cells in auto-immune disorders and degenerative disorders.
Education & Professional Highlights
Appointed
2010
Education & Fellowships
Fellowship - Fred Hutchinson Cancer Research Center
Pediatric Hematology-Oncology
Seattle,
WA
2010
Residency - Duke University Medical Center
Pediatrics
Durham,
NC
2007
Medical Education - Aleppo University Faculty of Medicine
Aleppo,
2001
Certifications
- Pediatrics - Pediatric Hematology-Oncology
- Pediatrics
Specialty Interests
Hematopoietic stem cell transplantation ( bone marrow transplantation, umbilical cord transplantation, Haplo-identical BMT), tolerance after transplant, pediatric hematology/oncology, leukemia and lymphoma, AYA, Primary immunodeficiency disorders, inherited metabolic and storage disorders
Research & Publications
See publications for Rabi Hanna, MD.
(Disclaimer: This search is powered by PubMed, a service of the U.S. National Library of Medicine. PubMed is a third-party website with no affiliation with Cleveland Clinic.)
Industry Relationships
Cleveland Clinic physicians and scientists may collaborate with the pharmaceutical or medical device industries to help develop medical breakthroughs or provide medical expertise or education. Cleveland Clinic strives to make scientific advances that will benefit patient care and support outside relationships that promise public benefit. In order for the discoveries of Cleveland Clinic physicians' and scientists' laboratories and investigations to benefit the public, these discoveries must be commercialized in partnership with industry. As experts in their fields, Cleveland Clinic physicians and scientists are often sought after by industry to consult, provide expertise and education.
To assure professional and commercial integrity in such matters, Cleveland Clinic maintains a program that reviews these collaborations and, when appropriate, puts measures in place to minimize bias that may result from ties to industry. Cleveland Clinic publicly discloses the names of companies when (i) its physicians/scientists receive $5,000 or more per year (or, in rare cases, equity or stock options) for speaking and consulting, (ii) its physicians/scientists serve as a fiduciary, (iii) its physicians/scientists receive or have the right to receive royalties or (iv) its physicians/ scientists hold any equity interest for the physician's/scientist's role as inventor, discoverer, developer, founder or consultant.* In publicly disclosing this information, Cleveland Clinic tries to provide information as accurately as possible about its physicians' and scientists' connections with industry.
As of 9/18/2024, Dr. Hanna has reported the financial relationships with the companies listed below. In general, patients should feel free to contact their doctor about any of the relationships and how the relationships are overseen by Cleveland Clinic. To learn more about Cleveland Clinic's policies on collaborations with industry and innovation management, go to our Integrity in Innovation page.
Consulting and/or Speaking. Dr. Hanna receives fees of $5,000 or more per year (or, in rare cases, equity or stock options) as a paid consultant, speaker or as a member of an advisory committee for the following companies:
- Sumitomo Dainippon Pharma Oncology, Inc.
- Swedish Orphan Biovitrum AB (Sobi)
- Sanofi Genzyme
- Vertex Pharmaceuticals Incorporated
- Chiesi USA, Inc.
Public Health Service-Reportable Financial Conflicts of Interest. Cleveland Clinic scientists and physicians engage in basic, translational and clinical research activities, working to solve health problems, enhance patient care and improve quality of life for patients. Interactions with industry are essential to bringing the researchers' discoveries to the public, but can present the potential for conflicts of interest related to their research activities. Click here to view a listing of instances where Cleveland Clinic has identified a Public Health Service (PHS)-Reportable Financial Conflict of Interest and has put measures in place to ensure that, to the extent possible, the design, conduct and reporting of the research is free from bias.
* Cleveland Clinic physicians and scientists subscribe to the guidance presented in the PhRMA Code on Interactions with Healthcare Professionals and the AdvaMed Code of Ethics on Interactions with Health Care Professionals. As such, gifts of substantial value are generally prohibited.
